Monthly headache frequency directly correlates with personal/societal burden and impacts severity and preventive treatment decisions. This post hoc analysis identified shifts from higher to lower frequency headache categories over 6聽months in patients with migraine participating in the PROMISE clinical trials receiving two eptinezumab doses.
Browse by Audience
Skip to content